GLOW

What GLOW is

GLOW is a research peptide blend comprising three distinct bioactive molecules: GHK-Cu, BPC-157, and TB-500. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring human tripeptide first isolated from human plasma albumin by researcher Loren Pickart in 1973 ^[1]. It was initially identified because it caused aged liver tissue to synthesize proteins at levels characteristic of younger tissue, and was subsequently found to have a high affinity for copper(II) ions, forming the chelate complex now known as GHK-Cu ^[2]. BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in gastric juice, which has been studied since the early 1990s primarily for its cytoprotective and wound-healing properties across multiple tissue types ^[3]. TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the endogenous 43-amino-acid protein thymosin beta-4, which was originally identified as a major actin-sequestering protein in thymus tissue ^[4]. All three components are classified as research peptides — small signaling molecules — and are not approved medications.

The rationale for combining the three components into a single blend rests on the hypothesis that their individual and complementary mechanisms — collagen induction (GHK-Cu), growth-factor-driven wound repair (BPC-157), and actin-mediated cell migration and angiogenesis (TB-500) — may act synergistically on skin regeneration and anti-aging pathways ^[5]. GHK plasma concentrations are documented to decline with age, from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60, a drop of more than 60%, which researchers have proposed may contribute to reduced regenerative capacity in older skin ^[6]. The GLOW blend is available exclusively for in vitro and preclinical research purposes.

What it is being researched for

1. Collagen and Extracellular Matrix Synthesis

GHK-Cu, the primary skin-targeted component of GLOW, has been extensively studied for its capacity to stimulate collagen synthesis in dermal fibroblasts. Early cell-culture work established that the tripeptide-copper complex increases synthesis of collagen types I, III, and IV, along with glycosaminoglycans such as dermatan sulfate and chondroitin sulfate ^[7]. It also stimulates the production of decorin, a small proteoglycan that helps organize collagen fibers and maintain skin architecture ^[1]. Parallel experiments have shown that GHK-Cu modulates the activity of matrix metalloproteinases (MMPs) — enzymes that degrade the extracellular matrix — and their tissue inhibitors (TIMPs), suggesting a dual role in both building and remodeling the dermal scaffold ^[7]. In one comparative human cosmetic trial, topical GHK-Cu applied for 12 weeks improved collagen production in 70% of participants, compared with 50% for vitamin C cream and 40% for retinoic acid ^[8]. BPC-157 has similarly been shown in animal wound models to increase collagen deposition at wound sites, with treated tissues displaying better organized collagen fibers resembling normal skin architecture rather than disorganized scar tissue ^[3].

2. Skin Anti-Aging and Wrinkle Reduction

Human clinical studies of GHK-Cu have examined its effects on the visible signs of photoaged and chronologically aged skin. A 12-week trial enrolling 71 women with mild to advanced photoaging found that a facial cream containing GHK-Cu increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth ^[8]. A separate eye-cream trial involving 41 women found that GHK-Cu outperformed both placebo and vitamin K cream for reducing periorbital lines and increasing skin density and thickness ^[8]. More recent randomized controlled work on low-molecular-weight collagen peptides broadly (though not GHK-Cu specifically) demonstrated significant improvements in wrinkle depth, height, and visual severity scores alongside improvements in skin elasticity and dermal density in a double-blind, placebo-controlled format ^[9]. Researchers have hypothesized that GHK-Cu's gene-modulating breadth — proposed to affect approximately 31% of analyzed human genes by resetting age-shifted expression toward younger profiles — may underpin its multi-parameter anti-aging activity ^[2].

3. Wound Healing and Dermal Re-Epithelialization

All three components of the GLOW blend have been studied for wound-healing activity, though through distinct mechanisms. BPC-157 was shown in a 2015 rat alkali-burn model to significantly accelerate wound closure, with histological findings demonstrating improved granulation tissue formation, faster re-epithelialization, enhanced dermal remodeling, and higher collagen deposition compared to controls ^[3]. An earlier mouse thermal-burn study found that BPC-157 cream completely reversed poor re-epithelialization by two weeks post-injury, with treated animals showing increased capillary formation and advanced development of collagen fibers ^[10]. Thymosin beta-4 (the parent protein of TB-500) increased re-epithelialization by 42% at day 4 and by as much as 61% at day 7 compared to saline controls in a rat full-thickness wound model ^[4]. GHK-Cu has also been studied in this context, with a Phase 2 randomized, double-blind clinical trial (NCT07437586) currently recruiting to evaluate topical GHK-Cu gel for accelerating re-epithelialization of standardized acute skin wounds in healthy adults ^[11].

4. Angiogenesis and Vascular Support

The formation of new blood vessels (angiogenesis) is a critical step in both wound healing and skin regeneration, and all three peptides in the GLOW blend have been studied in this context. GHK-Cu at nanomolar concentrations has been shown to increase expression of VEGF and basic FGF (bFGF) in irradiated human dermal fibroblasts and to stimulate HUVEC (human umbilical vein endothelial cell) proliferation, both of which support blood vessel formation in healing tissue ^[6]. TB-500 promotes endothelial cell migration and proliferation, tubular structure formation, and VEGF expression; proposed molecular mechanisms involve AKT/PI3K and ERK pathway activation ^[4]. BPC-157 similarly upregulated VEGF expression in wounded skin tissues and accelerated vascular tube formation in vitro in studies, with its healing mechanism linked to ERK1/2 signaling pathway activation ^[3]. Researchers have noted that TB-500 and BPC-157 appear to act on complementary vascular pathways, with TB-500 favoring angiogenesis and cytoskeletal remodeling while BPC-157 modulates wound healing via the nitric oxide pathway and VEGFR2 activation ^[5].

5. Antioxidant and Anti-Inflammatory Activity

Oxidative stress and chronic low-grade inflammation are considered central drivers of skin aging, and GHK-Cu has been studied for its capacity to counteract both. GHK-Cu has been shown to increase levels of antioxidant enzymes, including superoxide dismutase (SOD), by supplying bioavailable copper necessary for their function ^[2]. It also reduces levels of pro-inflammatory cytokines, including TNF-alpha and TGF-beta, and has been shown to suppress nuclear factor-kappa B (NF-κB), a master regulator of inflammatory gene expression ^[2]. Pretreatment of macrophage cell cultures with GHK-Cu significantly decreased reactive oxygen species (ROS) levels induced by pro-inflammatory stimuli ^[6]. In parallel, BPC-157 has demonstrated anti-inflammatory properties in animal wound models, with topical formulations decreasing edema and inflammatory markers at wound sites ^[3]. These antioxidant and anti-inflammatory properties are considered complementary to the collagen-stimulating effects and may help create a repair-permissive cellular environment in aged or damaged skin.

6. Skin Hydration, Elasticity, and Barrier Function

Skin hydration and elasticity are closely linked to the integrity of the dermal extracellular matrix, particularly glycosaminoglycan (GAG) content and collagen fiber organization. Early research by Siméon and Wegrowski demonstrated that GHK-Cu stimulates the synthesis of GAGs, increases chondroitin sulfate accumulation, and enhances type I collagen production, collectively contributing to improved skin elasticity, clarity, and smoothness ^[7]. Human collagen peptide supplementation trials have shown statistically significant improvements in surface and deep skin hydration, dermal density, and multiple elasticity parameters (R2, R5, R7) in double-blind, placebo-controlled settings ^[9]. A 2025 PMC study using liposome-encapsulated GHK-Cu additionally explored the permeation of the peptide through skin layers as a delivery challenge, noting that enhanced skin penetration formulations may improve GHK-Cu's efficacy for skin hydration and regeneration applications ^[12]. Research into improved delivery systems, including liposomal and ionic-liquid encapsulation, is an active area aimed at maximizing the peptide's bioavailability in skin tissue.

7. Gene Expression Modulation and Cellular Senescence

One of the more distinctive aspects of GHK-Cu research is its proposed ability to modulate gene expression at a broad, systems-biology scale. A Connectivity Map analysis cited in peer-reviewed literature found that GHK affects approximately 31% of analyzed human genes, with the net pattern of expression changes resembling a shift from aged to younger gene profiles ^[2]. The most affected pathways include antioxidant defense, DNA repair, ubiquitin-proteasome activity, and TGF-beta signaling ^[2]. GHK-Cu has additionally been found to stimulate epidermal basal stem cells, increasing integrin and p63 expression and causing cells to adopt a more cuboidal shape indicative of greater 'stemness' ^[8]. These observations, primarily from cell-culture and bioinformatic analyses, suggest that GHK-Cu may influence fundamental cellular aging programs, though translation of these findings to intact human tissue remains an active area of investigation.

How it is thought to work

The three components of the GLOW blend are proposed to act through distinct but potentially complementary molecular pathways. GHK-Cu functions as a copper-delivery and signaling molecule: it binds copper(II) ions and transports them into cells, where copper serves as a cofactor for enzymes essential to collagen cross-linking, including lysyl oxidase and lysyl hydroxylase ^[1]. Once internalized, the peptide stimulates fibroblasts to upregulate synthesis of collagen types I, III, and IV and glycosaminoglycans, while simultaneously modulating MMPs (which degrade matrix proteins) and TIMPs (which inhibit that degradation), thus tilting the balance toward extracellular matrix construction and remodeling ^[7]. GHK-Cu also increases VEGF and bFGF expression, promotes angiogenesis, reduces pro-inflammatory cytokines (TNF-alpha, TGF-beta), and activates antioxidant enzymes such as SOD — collectively creating a cellular environment favorable to repair and regeneration ^[2]. At the gene-expression level, GHK-Cu appears to modulate a remarkably broad set of human genes, with pathway analysis suggesting a net resetting of aging-associated expression patterns ^[2].

BPC-157 is proposed to act primarily through the ERK1/2 signaling pathway and via upregulation of VEGF and VEGFR2, promoting proliferation, migration, and tube formation by endothelial cells, which supports new blood vessel growth at wound sites ^[3]. It is also described as cytoprotective, stabilizing cellular junctions and modulating the nitric oxide pathway ^[5]. TB-500, the synthetic fragment of thymosin beta-4, operates chiefly by binding G-actin — the monomeric, unpolymerized form of actin — and redistributing it to sites where cells need to move or reorganize their cytoskeleton ^[4]. This actin-sequestering activity promotes keratinocyte migration (re-epithelialization), fibroblast movement and collagen deposition, and endothelial cell chemotaxis (angiogenesis). TB-500 also dampens inflammatory signaling during the repair phase, and its angiogenic effects are linked to AKT/PI3K and ERK signaling pathway activation ^[4]. Research has proposed that TB-500 and BPC-157 act on complementary vascular and repair axes, while GHK-Cu addresses the collagen-synthesis and gene-regulation layer of skin regeneration ^[5].

Where the evidence stands

The evidence base for the individual components of GLOW is tiered and uneven. GHK-Cu has the strongest and most directly skin-relevant clinical evidence of the three. Multiple small-to-moderate-scale human trials — including a 71-woman 12-week facial cream study and a 41-woman periorbital eye-cream study — have demonstrated improvements in skin density, thickness, fine lines, wrinkle depth, and skin laxity with topical GHK-Cu ^[8]. A comparative biopsy study found collagen improvements in 70% of GHK-Cu-treated participants versus 50% for vitamin C cream and 40% for retinoic acid ^[8]. These human trials are largely in the cosmetic rather than pharmaceutical domain and are limited by small sample sizes and manufacturer funding in some cases. A Phase 2 randomized, double-blind, vehicle-controlled trial of topical GHK-Cu gel for acute skin wound healing (NCT07437586) is currently recruiting, with completion estimated in 2028, which should provide more rigorous human efficacy data ^[11].

BPC-157 and TB-500, by contrast, have an evidence base that is overwhelmingly preclinical. A 2024 narrative review synthesizing literature from 1993–2024 identified only 36 studies meeting inclusion criteria for BPC-157 clinical evidence, and available human data for BPC-157 are limited to a small number of pilot studies with no published controlled human skin-aging or skin-repair trials ^[3]. Similarly, most published evidence on TB-500 comes from animal models and cell culture, with human data limited to early safety work ^[4]. As a combination blend, GLOW as a specific formulation has not been evaluated in any published controlled trial; the existing evidence refers to each component studied separately and predominantly in preclinical settings. A 2024 review concluded that 'rigorous, adequately powered human clinical trials are urgently needed before widespread clinical adoption can be recommended' for either BPC-157 or GHK-Cu ^[3]. Researchers should treat the current evidence as hypothesis-generating rather than conclusive, particularly for the combined-peptide blend.

Frequently asked questions

What is the GLOW peptide blend and what is it made of?

GLOW is a research peptide blend comprising three bioactive compounds: GHK-Cu (a naturally occurring human copper tripeptide), BPC-157 (a synthetic gastric-derived pentadecapeptide), and TB-500 (a synthetic fragment of the endogenous protein thymosin beta-4). Each component has been studied independently for roles in skin regeneration, collagen synthesis, and wound repair. The blend is intended exclusively for research purposes and is not approved for human therapeutic use.

Is the GLOW peptide blend FDA-approved or approved by Health Canada?

No. GHK-Cu, BPC-157, and TB-500 — individually and as a combination blend — are not approved by the FDA, Health Canada, or the EMA for therapeutic use in humans. They are classified as research compounds available for investigational and preclinical use only. No regulatory body has reviewed or approved the GLOW blend as a drug or medical treatment.

What does GHK-Cu do for skin in research?

In both cell-culture experiments and human cosmetic trials, GHK-Cu has been studied for its ability to stimulate collagen and elastin synthesis in dermal fibroblasts, modulate matrix-degrading enzymes, promote angiogenesis, and reduce inflammatory signaling. Human trials have reported improvements in skin density, firmness, fine lines, and wrinkle depth with topical application. Its effects on gene expression, potentially resetting aging-associated patterns toward younger profiles, are also an active area of preclinical investigation.

What is the evidence for BPC-157 in skin healing?

Published evidence for BPC-157 in skin healing is primarily from animal models, including rat alkali-burn and mouse thermal-burn studies, which showed accelerated wound closure, improved re-epithelialization, enhanced collagen deposition, and increased angiogenesis. Human clinical data are very limited, with no published controlled trials specifically examining BPC-157 for skin aging or cosmetic repair. The first Phase 2 controlled human trial of BPC-157 (for a musculoskeletal indication, not skin) began recruiting in 2026.

How is TB-500 different from thymosin beta-4?

TB-500 is a synthetic 7-amino-acid fragment derived from the actin-binding domain of the full 43-amino-acid protein thymosin beta-4. It retains much of the parent molecule's core biological activity — including actin sequestration, promotion of cell migration, and angiogenesis — but is a simpler, more easily synthesized molecule for research purposes. Some interactions that involve the full-length protein may be reduced or absent in the shorter fragment.

Are there any human clinical trials for the GLOW peptide components?

GHK-Cu has been evaluated in several human cosmetic trials demonstrating skin quality improvements with topical application, and a Phase 2 randomized controlled trial (NCT07437586) is currently recruiting to study topical GHK-Cu gel for acute wound healing. BPC-157 has only limited human safety and pilot data, with the first adequately designed controlled efficacy trial beginning recruitment in 2026. TB-500 has a small early-phase human safety dataset. No published human trial has evaluated the GLOW blend as a combined formulation.

What does 'research peptide' mean on a supplier's website?

The term 'research peptide' indicates that the compound is sold exclusively for use in laboratory or preclinical scientific research — not for human consumption, therapeutic use, or veterinary administration without appropriate regulatory approval. Research peptides have not undergone the clinical trial process required for regulatory approval as drugs. Purchasers are expected to be qualified researchers who will use the material according to applicable laws and institutional guidelines.

What skin benefits has GHK-Cu shown in human studies compared to retinol or vitamin C?

In one comparative biopsy study, topical GHK-Cu produced measurable collagen improvements in 70% of treated participants over 12 weeks, compared with 50% for a vitamin C cream and 40% for retinoic acid (a retinol derivative). A separate 71-woman facial cream trial reported improvements in skin density, thickness, laxity, clarity, and fine-line depth with GHK-Cu. These are relatively small trials, and head-to-head comparisons in large randomized controlled trials have not yet been published.

Can GLOW peptide research compounds cause side effects?

Available safety data are limited. GHK-Cu has been reported to be well tolerated in human topical cosmetic trials, with no serious adverse effects documented in published studies. BPC-157 and TB-500 animal studies have not revealed significant toxicity signals, and early human safety work on TB-500 found no reported serious adverse effects. However, neither compound has been evaluated in large-scale, long-term human safety trials, and the safety profile of the combined GLOW blend in humans is unknown.

Does GLOW peptide blend only affect skin, or are other tissues studied?

While GLOW is categorized as a skin and anti-aging research product, each component has been studied in broader biological contexts. GHK-Cu has been investigated for hepatoprotective effects, gastrointestinal mucosal repair, and bone tissue activity. BPC-157 has been studied across a range of tissues including tendons, ligaments, gastrointestinal mucosa, and muscle. TB-500 has been explored in cardiac repair, corneal injury, and musculoskeletal healing models. The skin and anti-aging categorization reflects the primary commercial research interest rather than the full scope of published preclinical investigation.

Glossary

GHK-Cu

Glycyl-L-histidyl-L-lysine copper(II) complex; a naturally occurring human tripeptide that chelates copper ions and is studied for collagen stimulation, wound healing, antioxidant activity, and gene expression modulation in skin.

BPC-157

Body Protective Compound-157; a synthetic pentadecapeptide (15 amino acids) derived from a gastric protein, studied in preclinical models for cytoprotective, wound-healing, and angiogenic properties.

TB-500

A synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the endogenous protein thymosin beta-4, studied for its roles in actin binding, cell migration, angiogenesis, and dermal wound repair.

Angiogenesis

The biological process by which new blood vessels form from pre-existing ones; essential for wound healing and tissue repair, and a key mechanism studied for all three components of the GLOW blend.

Matrix Metalloproteinases (MMPs)

A family of enzymes that degrade components of the extracellular matrix, including collagen; their balanced regulation by GHK-Cu is a proposed mechanism for dermal remodeling.

Re-epithelialization

The process by which epithelial (skin surface) cells migrate across a wound to restore the epidermal barrier; a primary outcome measured in wound-healing research involving BPC-157 and TB-500.

Glycosaminoglycans (GAGs)

Long, unbranched polysaccharide chains found in the extracellular matrix that contribute to skin hydration, elasticity, and structural support; their synthesis is stimulated by GHK-Cu in research models.

Fibroblast

The primary cell type of the dermis responsible for producing collagen, elastin, and glycosaminoglycans; the main cellular target studied in GHK-Cu skin-regeneration research.

References

1. Copper peptide GHK-Cu — Wikipedia overview including discovery by Loren Pickart (1973) — Wikipedia (citing primary peer-reviewed literature)
2. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — International Journal of Molecular Sciences / PubMed Central (PMC6073405)
3. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro — Drug Design, Development and Therapy / PubMed (PMID 25995620)
4. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — Journal of Chromatography B / ScienceDirect
5. TB-500 and BPC-157 synergy — TB-500 and Thymosin β-4: comprehensive guide to tissue regeneration research — Lab-Peptides France (citing peer-reviewed primary literature)
6. GHK-Cu tissue remodeling, VEGF/FGF expression, and plasma level decline with age — PubMed Central (PMC8789089)
7. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters — Journal of Aging Science, 2016
8. Regenerative and Protective Actions of the GHK-Cu Peptide — Cosmetic Use Section (71-woman and 41-woman human trials; collagen biopsy comparison data) — International Journal of Molecular Sciences / PubMed Central (PMC6073405)
9. Skin Anti-Aging and Moisturizing Effects of Low-Molecular-Weight Collagen Peptide Supplementation in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial — Journal of Microbiology and Biotechnology / PubMed Central (PMC12438954)
10. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice — Burns / PubMed (PMID 11718984)
11. NCT07437586: Topical GHK-Cu Gel for Acute Skin Wound Healing — Phase 2 Randomized Controlled Trial (Recruiting) — ClinicalTrials.gov
12. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? — Molecules / PubMed Central (PMC11721469)